Bio-Techne 경영진
경영진 기준 점검 4/4
Bio-Techne CEO는 Kim Kelderman, Feb2024 에 임명되었습니다 의 임기는 2.25 년입니다. 총 연간 보상은 $8.15M, 11.5% 급여 및 88.5% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.18M 가치에 해당하는 회사 주식의 0.042% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.8 년과 6.9 년입니다.
핵심 정보
Kim Kelderman
최고경영자
US$8.2m
총 보수
| CEO 급여 비율 | 11.48% |
| CEO 재임 기간 | 2.3yrs |
| CEO 지분 보유율 | 0.04% |
| 경영진 평균 재임 기간 | 2.8yrs |
| 이사회 평균 재임 기간 | 6.9yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Apr 20
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.내러티브 업데이트 • Apr 05
TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).내러티브 업데이트 • Mar 22
TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).내러티브 업데이트 • Mar 06
TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).
내러티브 업데이트 • Feb 20
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.분석 기사 • Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Shareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...내러티브 업데이트 • Feb 05
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).내러티브 업데이트 • Jan 22
TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 08
TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).내러티브 업데이트 • Dec 16
TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).내러티브 업데이트 • Dec 01
TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.내러티브 업데이트 • Nov 17
TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).분석 기사 • Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...내러티브 업데이트 • Nov 03
TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.내러티브 업데이트 • Oct 20
Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.내러티브 업데이트 • Aug 27
Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.분석 기사 • Jul 28
Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Corporation's ( NASDAQ:TECH ) price-to-earnings (or "P/E") ratio of 70x might make it look like a strong...분석 기사 • May 29
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?
Bio-Techne Corporation ( NASDAQ:TECH ), might not be a large cap stock, but it saw significant share price movement...Seeking Alpha • Feb 27
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Summary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking Alpha
새 내러티브 • Aug 22
Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges
Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$109m |
| Dec 31 2025 | n/a | n/a | US$81m |
| Sep 30 2025 | n/a | n/a | US$78m |
| Jun 30 2025 | US$8m | US$936k | US$73m |
| Mar 31 2025 | n/a | n/a | US$132m |
| Dec 31 2024 | n/a | n/a | US$158m |
| Sep 30 2024 | n/a | n/a | US$151m |
| Jun 30 2024 | US$7m | US$760k | US$168m |
| Mar 31 2024 | n/a | n/a | US$203m |
| Dec 31 2023 | n/a | n/a | US$224m |
| Sep 30 2023 | n/a | n/a | US$247m |
| Jun 30 2023 | US$3m | US$590k | US$285m |
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$3m | US$562k | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$4m | US$530k | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$2m | US$500k | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$2m | US$452k | US$96m |
보상 대 시장: Kim의 총 보수(USD8.15M)는 US 시장에서 비슷한 규모 기업의 평균(USD8.41M) 수준입니다.
보상과 수익: Kim의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Kim Kelderman (57 yo)
2.3yrs
재임 기간
US$8,151,180
보수
Mr. Kim Kelderman is Director of Biorez, Inc. from 2025. Mr. Kelderman is Director of CONMED Corporation from September 8, 2025. Mr. Kelderman serves as Director of SLMP, LLC since November 2021.He served...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | 2.3yrs | US$8.15m | 0.042% $ 3.2m | |
| Executive VP of Finance & CFO | 12.1yrs | US$7.03m | 0.098% $ 7.4m | |
| Senior VP | 3.2yrs | US$1.98m | 0.0046% $ 350.6k | |
| President of Protein Sciences Segment | 4.3yrs | US$3.14m | 0.013% $ 991.9k | |
| VP & CTO | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| VP of Investor Relations & Corporate Development | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of Sales and Marketing | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Strategy & Corporate Development | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Human Resources Officer | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Managing Director | 9.8yrs | 데이터 없음 | 데이터 없음 | |
| President of Diagnostics and Spatial Biology Segment | 3.3yrs | 데이터 없음 | 0.0040% $ 306.7k | |
| Senior Vice President of Bio-Techne Diagnostics Division | 2.3yrs | 데이터 없음 | 데이터 없음 |
2.8yrs
평균 재임 기간
54yo
평균 나이
경험이 풍부한 관리: TECH의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.8 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | 3.3yrs | US$8.15m | 0.042% $ 3.2m | |
| Independent Chairman of the Board | 23.3yrs | US$400.42k | 0.030% $ 2.2m | |
| Independent Director | 17yrs | US$300.42k | 0.043% $ 3.2m | |
| Independent Director | 9.3yrs | US$275.42k | 0.0098% $ 745.1k | |
| Independent Director | 5.8yrs | US$292.92k | 0.0056% $ 424.0k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 9.3yrs | US$285.42k | 0.0098% $ 745.1k | |
| Independent Director | 1.3yrs | US$181.36k | 0.0018% $ 139.3k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.1yrs | US$275.35k | 0.0024% $ 183.2k | |
| Independent Director | 6.9yrs | US$275.42k | 0.0070% $ 531.5k |
6.9yrs
평균 재임 기간
62yo
평균 나이
경험이 풍부한 이사회: TECH의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.9 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/11 09:54 |
| 종가 | 2026/05/11 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Bio-Techne Corporation는 25명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Wasserman | Benchmark Company |